Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patients
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.10.07.21264491: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: The study protocol was approved by an in-house ethical committee constituted by CRO and conducted from 17 Sep 2020 to 24 Sep. 2020. 2.2.
IRB: The IEC approval for the study was obtained from Vedant Hospital Institutional Ethics Committee (VHIEC) and Lifepoint Research Ethics committee on January 13, 2021 and March 13, 2021.Sex as a biological variable not detected. Randomization Phase 2 clinical trial: The single-blind, placebo-controlled, randomized clinical trial was designed to evaluate the tolerability of plant formulation (ATRICOV 452) its impact on the level of COVID-19 specific inflammatory markers in adult COVID-19 patients under standard of care also. Blinding All outcome … SciScore for 10.1101/2021.10.07.21264491: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: The study protocol was approved by an in-house ethical committee constituted by CRO and conducted from 17 Sep 2020 to 24 Sep. 2020. 2.2.
IRB: The IEC approval for the study was obtained from Vedant Hospital Institutional Ethics Committee (VHIEC) and Lifepoint Research Ethics committee on January 13, 2021 and March 13, 2021.Sex as a biological variable not detected. Randomization Phase 2 clinical trial: The single-blind, placebo-controlled, randomized clinical trial was designed to evaluate the tolerability of plant formulation (ATRICOV 452) its impact on the level of COVID-19 specific inflammatory markers in adult COVID-19 patients under standard of care also. Blinding All outcome assessors, investigators, and research staff who were involved in the trial were blinded to participant treatment assignment. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
